The role of the hepatitis viruses in cholangiocarcinoma

Journal of Viral Hepatitis

Volumn 20, Issue 5, 2013, Pages 297-305

  Ralphs, S ^a   Khan, Shahid A ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

cholangiocarcinoma; epidemiology; hepatitis B; hepatitis C; pathogenesis

Indexed keywords

CORE PROTEIN; HEPATITIS B VIRUS X PROTEIN; ONCOPROTEIN;

BILE DUCT CARCINOMA; CHOLESTASIS; HEPATITIS; HEPATITIS B; HEPATITIS C; HEPATITIS VIRUS; HUMAN; INCIDENCE; INFECTION RISK; LIVER CELL CARCINOMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

CHOLANGIOCARCINOMA; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HEPATITIS VIRUSES; HUMANS; INCIDENCE; RISK FACTORS;

EID: 84876033954     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12093     Document Type: Review

References (87)

1. Taylor-Robinson SD, Toledano MB, Arora S, et al,. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998. Gut 2001; 48: 816-820. (Pubitemid 32479209)
2. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC,. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002; 37: 806-813. (Pubitemid 35404220)
3. Khan SA, Davidson BR, Goldin RD, et al,. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 2012; 61: 1657-1669.
4. Shaib Y, El-Serag HB,. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004; 24: 115-125. (Pubitemid 38738341)
5. Patel T,. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33: 1353-1357. (Pubitemid 32496970)
6. Patel T,. Worldwide trends in mortality from biliary tract malignancies. BMC cancer 2002; 2: 10.
7. Blechacz B, Komuta M, Roskams T, Gores GJ,. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2011; 8: 512-522.
8. Shaib YH, Davila JA, McGlynn K, El-Serag HB,. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004; 40: 472-477. (Pubitemid 38230849)
9. Khan SA, Emadossadaty S, Ladep NG, et al,. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol 2012; 56: 848-854.
10. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD,. Cholangiocarcinoma. Lancet 2005; 366: 1303-1314. (Pubitemid 41416587)
11. Tyson GL, El-Serag HB,. Risk factors for cholangiocarcinoma. Hepatology 2011; 54: 173-184.
12. Palmer WC, Patel T,. Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol 2012; 57: 69-76.
13. Sithithaworn P, Andrews RH, Nguyen VD, et al,. The current status of opisthorchiasis and clonorchiasis in the Mekong Basin. Parasitol Int 2012; 61: 10-16.
14. Lun ZR, Gasser RB, Lai DH, et al,. Clonorchiasis: a key foodborne zoonosis in China. Lancet Infect Dis 2005; 5: 31-41. (Pubitemid 40037627)
15. Choi D, Lim JH, Lee KT, et al,. Cholangiocarcinoma and Clonorchis sinensis infection: a case-control study in Korea. J Hepatol 2006; 44: 1066-1073.
16. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994; 61: 1-241.
17. Parkin DM, Srivatanakul P, Khlat M, et al,. Liver cancer in Thailand. I. A case-control study of cholangiocarcinoma. Int J Cancer 1991; 48: 323-328.
18. Shin HR, Lee CU, Park HJ, et al,. Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. Int J Epidemiol 1996; 25: 933-940.
19. Donato F, Gelatti U, Tagger A, et al,. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control 2001; 12: 959-964. (Pubitemid 34048878)
20. Yamamoto S, Kubo S, Hai S, et al,. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci 2004; 95: 592-595. (Pubitemid 39089641)
21. Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA,. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005; 128: 620-626. (Pubitemid 40585364)
22. Shaib YH, El-Serag HB, Nooka AK, et al,. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol 2007; 102: 1016-1021. (Pubitemid 46698225)
23. Welzel TM, Graubard BI, El-Serag HB, et al,. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 2007; 5: 1221-1228. (Pubitemid 47496233)
24. Hsing AW, Zhang M, Rashid A, et al,. Hepatitis B and C virus infection and the risk of biliary tract cancer: a population-based study in China. Int J Cancer 2008; 122: 1849-1853. (Pubitemid 351413433)
25. Lee TY, Lee SS, Jung SW, et al,. Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study. Am J Gastroenterol 2008; 103: 1716-1720.
26. Zhou YM, Yin ZF, Yang JM, et al,. Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. World J Gastroenterol 2008; 14: 632-635.
27. Lee CH, Chang CJ, Lin YJ, Yeh CN, Chen MF, Hsieh SY,. Viral hepatitis-associated intrahepatic cholangiocarcinoma shares common disease processes with hepatocellular carcinoma. Br J Cancer 2009; 100: 1765-1770.
28. Tao LY, He XD, Qu Q, et al,. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a case-control study in China. Liver Int 2010; 30: 215-221.
29. El-Serag HB, Engels EA, Landgren O, et al,. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans. Hepatology 2009; 49: 116-123.
30. Zhou H, Wang H, Zhou D, et al,. Hepatitis B virus-associated intrahepatic cholangiocarcinoma and hepatocellular carcinoma may hold common disease process for carcinogenesis. Eur J Cancer 2010; 46: 1056-1061.
31. Peng NF, Li LQ, Qin X, et al,. Evaluation of risk factors and clinicopathologic features for intrahepatic cholangiocarcinoma in Southern China: a possible role of hepatitis B virus. Ann Surg Oncol 2011; 18: 1258-1266.
32. Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA,. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011; 54: 463-471.
33. Qu Z, Cui N, Qin M, Wu X,. Epidemiological survey of biomarkers of hepatitis virus in patients with extrahepatic cholangiocarcinomas. Asia Pac J Clin Oncol 2012; 8: 83-87.
34. Tanaka M, Tanaka H, Tsukuma H, Ioka A, Oshima A, Nakahara T,. Risk factors for intrahepatic cholangiocarcinoma: a possible role of hepatitis B virus. J Viral Hepatitis 2010; 17: 742-748.
35. Fwu CW, Chien YC, You SL, et al,. Hepatitis B virus infection and risk of intrahepatic cholangiocarcinoma and non-Hodgkin lymphoma: a cohort study of parous women in Taiwan. Hepatology 2011; 53: 1217-1225.
36. Hadler SC, Murphy BL, Schable CA, Heyward WL, Francis DP, Kane MA,. Epidemiological analysis of the significance of low-positive test results for antibody to hepatitis B surface and core antigens. J Clin Microbiol 1984; 19: 521-525. (Pubitemid 14161861)
37. Zhou Y, Zhao Y, Li B, et al,. Hepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: evidence from a meta-analysis. BMC cancer 2012; 12: 289.
38. Li M, Li J, Li P, et al,. Hepatitis B virus infection increases the risk of cholangiocarcinoma: a meta-analysis and systematic review. J Gastroenterol Hepatol 2012; 27: 1561-1568.
39. Wang WL, Gu GY, Hu M,. Expression and significance of HBV genes and their antigens in human primary intrahepatic cholangiocarcinoma. World J Gastroenterol 1998; 4: 392-396. (Pubitemid 128620198)
40. Zhou YM, Cao L, Li B, Zhang XZ, Yin ZF,. Expression of HBx protein in hepatitis B virus-infected intrahepatic cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2012; 11: 532-535.
41. Liu HB, Qian ZY, Wang BS, Tong SX,. Detection of markers of hepatitis viral infection in the tissue of bile duct carcinoma. Chin Med J 2008; 121: 1143-1144.
42. Perumal V, Wang J, Thuluvath P, Choti M, Torbenson M,. Hepatitis C and hepatitis B nucleic acids are present in intrahepatic cholangiocarcinomas from the United States. Hum Pathol 2006; 37: 1211-1216. (Pubitemid 44286989)
43. Yin F, Chen B,. Detection of hepatitis C virus RNA sequences in hepatic portal cholangiocarcinoma tissue by reverse transcription polymerase chain reaction. Chin Med J 1998; 111: 1068-1070.
44. Lu H, Ye MQ, Thung SN, Dash S, Gerber MA,. Detection of hepatitis C virus RNA sequences in cholangiocarcinomas in Chinese and American patients. Chin Med J 2000; 113: 1138-1141.
45. Chen RF, Li ZH, Zou SQ, Chen JS,. Effect of hepatitis C virus core protein on modulation of cellular proliferation and apoptosis in hilar cholangiocarcinoma. Hepatobiliary Pancreat Dis Int 2005; 4: 71-74.
46. Petersen BE, Goff JP, Greenberger JS, Michalopoulos GK,. Hepatic oval cells express the hematopoietic stem cell marker Thy-1 in the rat. Hepatology 1998; 27: 433-445. (Pubitemid 28081058)
47. Cho NJ, Elazar M, Xiong A, et al,. Viral infection of human progenitor and liver-derived cells encapsulated in three-dimensional PEG-based hydrogel. Biomed Mater 2009; 4: 011001.
48. Lowes KN, Brennan BA, Yeoh GC, Olynyk JK,. Oval cell numbers in human chronic liver diseases are directly related to disease severity. Am J Pathol 1999; 154: 537-541. (Pubitemid 29094103)
49. Xiao JC, Jin XL, Ruck P, Adam A, Kaiserling E,. Hepatic progenitor cells in human liver cirrhosis: immunohistochemical, electron microscopic and immunofluorescence confocal microscopic findings. World J Gastroenterol 2004; 10: 1208-1211. (Pubitemid 38559401)
50. Wang C, Yang W, Yan HX, et al,. Hepatitis B virus X (HBx) induces tumorigenicity of hepatic progenitor cells in 3,5-diethoxycarbonyl-1,4- dihydrocollidine-treated HBx transgenic mice. Hepatology 2012; 55: 108-120.
51. Yu TH, Yuan RH, Chen YL, Yang WC, Hsu HC, Jeng YM,. Viral hepatitis is associated with intrahepatic cholangiocarcinoma with cholangiolar differentiation and N-cadherin expression. Mod Pathol 2011; 24: 810-819.
52. Grivennikov SI, Greten FR, Karin M,. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.
53. Schottenfeld D, Beebe-Dimmer J,. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin 2006; 56: 69-83.
54. Bertoletti A, Ferrari C,. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 2012; 61: 1754-1764.
55. Das A, Maini MK,. Innate and adaptive immune responses in hepatitis B virus infection. Dig Dis 2010; 28: 126-132.
56. Cheon YK, Cho YD, Moon JH, et al,. Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Am J Gastroenterol 2007; 102: 2164-2170. (Pubitemid 47493842)
57. Goydos JS, Brumfield AM, Frezza E, Booth A, Lotze MT, Carty SE,. Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker. Ann Surg 1998; 227: 398-404. (Pubitemid 28131021)
58. Okada K, Shimizu Y, Nambu S, Higuchi K, Watanabe A,. Interleukin-6 functions as an autocrine growth factor in a cholangiocarcinoma cell line. J Gastroenterol Hepatol 1994; 9: 462-467. (Pubitemid 24312840)
59. Park J, Tadlock L, Gores GJ, Patel T,. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology 1999; 30: 1128-1133. (Pubitemid 29510848)
60. Isomoto H, Kobayashi S, Werneburg NW, et al,. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 2005; 42: 1329-1338. (Pubitemid 43260035)
61. Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH, Gores GJ,. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology 2005; 128: 2054-2065. (Pubitemid 40824713)
62. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ,. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000; 60: 184-190. (Pubitemid 30058750)
63. Korenaga M, Wang T, Li Y, et al,. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem 2005; 280: 37481-37488. (Pubitemid 41642356)
64. Poreba E, Broniarczyk JK, Gozdzicka-Jozefiak A,. Epigenetic mechanisms in virus-induced tumorigenesis. Clin Epigenetics 2011; 2: 233-247.
65. Murakami S, Hepatitis B,. virus X protein: a multifunctional viral regulator. J Gastroenterol 2001; 36: 651-660. (Pubitemid 33040937)
66. Feitelson MA, Duan LX,. Hepatitis B virus X antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma. Am J Pathol 1997; 150: 1141-1157. (Pubitemid 27152632)
67. Kim CM, Koike K, Saito I, Miyamura T, Jay G,. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991; 351: 317-320. (Pubitemid 21896589)
68. Sirma H, Giannini C, Poussin K, Paterlini P, Kremsdorf D, Brechot C,. Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. Oncogene 1999; 18: 4848-4859. (Pubitemid 29423568)
69. Lee JO, Kwun HJ, Jung JK, Choi KH, Min DS, Jang KL,. Hepatitis B virus X protein represses E-cadherin expression via activation of DNA methyltransferase 1. Oncogene 2005; 24: 6617-6625. (Pubitemid 41486792)
70. Zhu YZ, Zhu R, Fan J, et al,. Hepatitis B virus X protein induces hypermethylation of p16(INK4A) promoter via DNA methyltransferases in the early stage of HBV-associated hepatocarcinogenesis. J Viral Hepatitis 2010; 17: 98-107.
71. Wang XW, Yeh H, Schaeffer L, et al,. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat Genet 1995; 10: 188-195.
72. Ueda H, Ullrich SJ, Gangemi JD, et al,. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet 1995; 9: 41-47.
73. White E,. Life, death, and the pursuit of apoptosis. Genes Dev 1996; 10: 1-15. (Pubitemid 26025294)
74. Su Q, Liu YF, Zhang JF, Zhang SX, Li DF, Yang JJ,. Expression of insulin-like growth factor II in hepatitis B, cirrhosis and hepatocellular carcinoma: its relationship with hepatitis B virus antigen expression. Hepatology 1994; 20: 788-799. (Pubitemid 24296482)
75. Koike K, Moriya K, Yotsuyanagi H, Iino S, Kurokawa K,. Induction of cell cycle progression by hepatitis B virus HBx gene expression in quiescent mouse fibroblasts. J Clin Invest 1994; 94: 44-49. (Pubitemid 24218075)
76. Benn J, Schneider RJ,. Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls. Proc Natl Acad Sci USA 1995; 92: 11215-11219.
77. Yang B, House MG, Guo MZ, Herman JG, Clark DP,. Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Modern Pathol 2005; 18: 412-420. (Pubitemid 40395361)
78. Qu ZL, Zou SQ, Cui NQ, et al,. Upregulation of human telomerase reverse transcriptase mRNA expression by in vitro transfection of hepatitis B virus X gene into human hepatocarcinoma and cholangiocarcinoma cells. World J Gastroenterol 2005; 11: 5627-5632.
79. Chen CJ, Kyo S, Liu YC, et al,. Modulation of human telomerase reverse transcriptase in hepatocellular carcinoma. World J Gastroenterol 2004; 10: 638-642. (Pubitemid 38351527)
80. Zou SQ, Qu ZL, Li ZF, Wang X,. Hepatitis B virus X gene induces human telomerase reverse transcriptase mRNA expression in cultured normal human cholangiocytes. World J Gastroenterol 2004; 10: 2259-2262. (Pubitemid 39144979)
81. Djojosubroto MW, Choi YS, Lee HW, Rudolph KL,. Telomeres and telomerase in aging, regeneration and cancer. Mol Cells 2003; 15: 164-175. (Pubitemid 41582919)
82. Liang TJ, Heller T,. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology 2004; 127: S62-S71. (Pubitemid 39423371)
83. Levrero M,. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006; 25: 3834-3847. (Pubitemid 43980479)
84. Chen RF, Li ZH, Liu RY, Kong XH, Tang QB, Wang J,. Malignant transformation of the cultured human normal biliary tract epithelial cells induced by hepatitis C virus core protein. Oncol Rep 2007; 17: 105-110.
85. Guo N, Chen R, Li Z, et al,. Hepatitis C virus core upregulates the methylation status of the RASSF1A promoter through regulation of SMYD3 in hilar cholangiocarcinoma cells. Acta Biochim Biophys Sin 2011; 43: 354-361.
86. Zeng B, Li Z, Chen R, et al,. Epigenetic regulation of miR-124 by hepatitis C virus core protein promotes migration and invasion of intrahepatic cholangiocarcinoma cells by targeting SMYD3. FEBS Lett 2012; 586: 3271-3278.
87. Liu W, Chen JR, Hsu CH, et al,. A zebrafish model of intrahepatic cholangiocarcinoma by dual expression of hepatitis B virus X and hepatitis C virus core protein in liver. Hepatology 2012; 56: 2268-2276.